Tagraxofusp

Tagraxofusp-erzs (trade name Elzonris) is a drug for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). It was approved for use in the United States in 2018.[1]

Tagraxofusp
Clinical data
Trade namesElzonris
Other namesDT388-IL3; SL-401
Identifiers
CAS Number
DrugBank
UNII

Tagraxofusp-erzs is a fusion protein consisting of interleukin 3 (IL-3) fused to diphtheria toxin.[2] The fusion protein readily kills cultured pDC by binding to their IL-3 receptors to thereby gain entrance to the cells and then blocking these cells' protein synthesis (due to its diphtheria toxin portion inhibiting eukaryotic elongation factor 2).

References
  1. "FDA approves first treatment for rare blood disease" (Press release). Food and Drug Administration. December 21, 2018.
  2. "ELZONRIS (tagraxofusp, SL-401)". Stemline Therapeutics.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.